Page last updated: 2024-10-25

deferoxamine and Pneumocystis Infections

deferoxamine has been researched along with Pneumocystis Infections in 1 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Pneumocystis Infections: Infections with species in the genus PNEUMOCYSTIS, a fungus causing interstitial plasma cell pneumonia (PNEUMONIA, PNEUMOCYSTIS) and other infections in humans and other MAMMALS. Immunocompromised patients, especially those with AIDS, are particularly susceptible to these infections. Extrapulmonary sites are rare but seen occasionally.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Weinberg, GA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations[NCT04333550]Phase 1/Phase 250 participants (Anticipated)Interventional2020-04-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for deferoxamine and Pneumocystis Infections

ArticleYear
Iron chelators as therapeutic agents against Pneumocystis carinii.
    Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:5

    Topics: Animals; Cells, Cultured; Deferoxamine; Fibroblasts; Humans; Immunosuppression Therapy; Iron Chelati

1994